e-learning
resources
Paris 2018
Monday, 17.09.2018
Lung cancer: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy>
M. Hung (Puzi city, Taiwan), M. Chuang (Puzi city, Taiwan), Y. Tsai (Puzi city, Taiwan), Y. Yang (Puzi city, Taiwan)
Source:
International Congress 2018 – Lung cancer: from the bench to the bedside
Session:
Lung cancer: from the bench to the bedside
Session type:
Thematic Poster
Number:
2856
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Hung (Puzi city, Taiwan), M. Chuang (Puzi city, Taiwan), Y. Tsai (Puzi city, Taiwan), Y. Yang (Puzi city, Taiwan). Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy>. 2856
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Dexamethasone improves antiemetic control in lung cancer patients treated with chemotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007
Mianserin therapy in advanced lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 367s
Year: 2002
Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004
Combination of erlotinib and bevacizumab in non small cell lung cancer patients
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Biphosphonate, ibantronate improves analgesic therapy in non-small lung cancer (NSCLC) patients with bone metastases
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017
Year: 2018
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006
Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Survival of elderly patients with non-small lung cancer tretaed with combined chemotherapy and radiotherapy
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Outcome after pneumonectomy in non small cell lung cancer patients receiving a neoadjuvant therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 478s
Year: 2004
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept